Can-fite Biopharma Ltd. · TASE:CANF
Can-fite Biopharma — Investor Presentation (September 2019)
19 slides from Can-fite Biopharma's investor presentation, Sep 6, 2019
Slide 1: Can-Fite Presentation September 2019
(NYSE American: CANF) (TASE:CFBI) Can - Fite Presentation September 2019 (NYSE American: CANF) (TASE:CFBI)
Slide 2: Forward Looking Statement
(NYSE American: CANF) (TASE:CFBI) Forward Looking Statement 2 • This presentation contains forward - looking statements, about Can - Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strate
Slide 3: Company Profile
(NYSE American: CANF) (TASE:CFBI) 3 Company Profile • Highly experienced management, clinical and regulatory team • Leading KOLs serve on CAB • Successful corporate partnerships and licensing deals • Advanced clinical stage drug development company with a compelling platform technology • Small molec
Slide 4: From Concept to Technology
(NYSE American: CANF) (TASE:CFBI) From Concept to Technology 4 Company platform technology mimics natural body mechanism to combat cancer and inflammation
Slide 5: Platform Technology: A3 Adenosine Receptor
(NYSE American: CANF) (TASE:CFBI) Therapeutic Target • A 3 adenosine receptor (A 3 AR) • Highly expressed in inflammatory and cancer cells Drug product • Small molecules • Orally bioavailable drugs Therapeutic Effect • Anti - inflammatory and anti - cancer effects shown in Phase II studies; Excellen
Slide 6: Drug Development Pipeline
(NYSE American: CANF) (TASE:CFBI) Drug Development Pipeline 6 ~$ 35 B ~$11.4B ~$ 3.8 B ~$35B ~$3.2B Market *Sources: Visiongain estimates global psoriasis drug market will be $ 11.4 bB by 2020 and the global rheumatoid arthritis drug market will be $ 34.6 B by 2020 ; DelveInsight estimates the HCC d
Slide 7: Corporate Partnerships: Out-licensing deals
(NYSE American: CANF) (TASE:CFBI) Corporate Partnerships: Out - licensing deals 7 ~$18 million* upfront and milestone payments received to date for licensing and distribution deals $8.5M was from a license with a Japanese company, SKK; the license was terminated due to SKK’s strategic change of focu
Slide 8: Piclidenoson Rheumatoid Arthritis & Psoriasis
(NYSE American: CANF) (TASE:CFBI) 8 Piclidenoson Rheumatoid Arthritis & Psoriasis Piclidenoson – Anti - Inflammatory Drug Mechanism of Action
Slide 9: Rheumatoid Arthritis - Phase IIb Data
(NYSE American: CANF) (TASE:CFBI) Phase IIb study, Placebo controlled; 79 patients – Positively concluded Rheumatoid Arthritis - Phase IIb Data 9 *MTX, Biological Drugs *MTX, Biological Drugs Patients with No Prior Systemic Therapy* ACR20 ACR50 ACR 70 ACR Response Rates Placebo (n=8) Piclidenoson (n
Slide 10: Rheumatoid Arthritis - Phase III Study Ongoing
(NYSE American: CANF) (TASE:CFBI) Rheumatoid Arthritis - Phase III Study Ongoing ACRobat – Can - Fite’s Phase III clinical study is designed to establish Piclidenoson as non - inferior to MTX in newly diagnosed patients with moderate - to - severe RA This Protocol is in Agreement with EMA • Randomiz
Slide 11: Psoriasis Phase II/III Data vs. Celgene's Otezla
(NYSE American: CANF) (TASE:CFBI) Psoriasis Phase II/III Data vs. Celgene’s Otezla * 11 • Phase II/III study did not achieve the primary endpoint of PASI 75 at 12 weeks • Otezla® sales were $1.3 billion in 2017, 26% increase over 2016 1 • Peak Otezla® sales estimated at $2.35 billion in 2020 2 • Pha
Slide 12: Psoriasis Phase III Study - Ongoing
(NYSE American: CANF) (TASE:CFBI) Psoriasis Phase III Study - Ongoing Comfort – Phase III clinical study is designed to establish Piclidenoson superiority vs. placebo and non - inferiorty vs. Otezla in patients with moderate - to - severe Plaque Psoriasis This Protocol is in Agreement with EMA • Ran
Slide 13: Namodenoson Advanced Liver Cancer & NASH
(NYSE American: CANF) (TASE:CFBI) 13 Namodenoson Advanced Liver Cancer & NASH Namodenoson – Liver Disease Drug Mechanism of Action
Slide 14: Phase II Study – Advanced Liver Cancer
(NYSE American: CANF) (TASE:CFBI) Phase II - Study Protocol • Second - Line Treatment • Advanced Hepatocellular Carcinoma; Child - Pugh B • 78 patients • US, Europe and Israel • Primary end point: overall survival • Patient enrollment completed August 2017 Regulatory Status • FDA and EMA have grante
Slide 15: Phase II – Advanced Liver Cancer Results
(NYSE American: CANF) (TASE:CFBI) • While the study (78 patients) did not achieve its primary endpoint, it did achieve superiority in survival in the largest subpopulation of CPB7, 56 patients - 6.8 month median overall survival vs. 4.3 months for placebo • CPB7 group treated with Namodenoson had 44
Slide 16: Namodenoson for the Treatment of NASH
(NYSE American: CANF) (TASE:CFBI) Namodenoson for the Treatment of NASH 16 Sources: 1) Study published in Hepatology, 2) NIH, 3) Study published in Gastroenterology, 4) Deutsche Bank “ America’s Greatest Health Risk” – Scientific American, 2015 x 17% - 33% Prevalence of NAFLD in the U.S. 1 x 2 - 5%
Slide 17: NASH – Excellent Pre-clinical Data
(NYSE American: CANF) (TASE:CFBI) NASH – Excellent Pre - clinical Data 17 Namodenoson markedly improved liver function & pathology in NASH experimental models (STAM & CCL4) x Anti - inflammatory - Namodenoson reduces NAFLD Activity Score (NAS) in STAM model x Anti - Fibrotic effect - in vitro and in
Slide 18: NASH – Phase II Study
(NYSE American: CANF) (TASE:CFBI) NASH – Phase II Study 18 Leading KOLs ( Dr. Freidman ; Mount Sinai, Dr. Arun Sanyal ; Virginia University, Dr. Safadi ; Hadassah Jerusalem), on SAB and have advised on protocol design • Multicenter, randomized, double - blinded, placebo - controlled, dose - finding
Slide 19: Spotlight on Milestones
(NYSE American: CANF) (TASE:CFBI) Spotlight on Milestones 19 *Sources: Visiongain estimates global psoriasis drug market will be $11.4 by 2020 and the global rheumatoid arthritis drug ma rke t will be $34.6b by 2020; DelseInsight estimates the HCC drug market at $3.8 b in 2027; Grand View Research e
Can-Fite BioPharma — Investor Presentation (September 2019) on 6ix